MCID: GRN017
MIFTS: 44

Granulocytopenia

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Granulocytopenia

MalaCards integrated aliases for Granulocytopenia:

Name: Granulocytopenia 52
Agranulocytosis 71 32

Classifications:



External Ids:

ICD10 32 D70
UMLS 71 C0001824

Summaries for Granulocytopenia

MalaCards based summary : Granulocytopenia, also known as agranulocytosis, is related to neutropenia, severe congenital, 3, autosomal recessive and cyclic neutropenia. An important gene associated with Granulocytopenia is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Omeprazole and Cefpirome have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and lung, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Granulocytes are a category of white blood cells in the innate immune system characterized by the... more...

Related Diseases for Granulocytopenia

Diseases related to Granulocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)
# Related Disease Score Top Affiliating Genes
1 neutropenia, severe congenital, 3, autosomal recessive 33.7 IL3 CSF3 CSF2
2 cyclic neutropenia 32.3 TNF IL3 CSF3 CSF2
3 felty syndrome 30.4 IL3 CSF3 CSF2
4 shwartzman phenomenon 30.4 TNF ITGAM
5 leukostasis 30.3 TNF SELL MPO
6 soft tissue sarcoma 30.2 TNF CSF3
7 thrombocytosis 30.2 IL3 CSF3 CSF2
8 aspergillosis 30.2 TNF CSF3 CSF2
9 acute leukemia 30.1 MPO IL3 CSF3 CSF2
10 mucormycosis 30.1 CSF3 CSF2
11 miliary tuberculosis 30.1 TNF CSF3
12 large granular lymphocyte leukemia 30.0 CSF3 CSF2
13 stomatitis 30.0 TNF CSF3 CSF2
14 pulmonary tuberculosis 29.9 TNF NAT2 CP
15 gingivitis 29.9 TNF MPO CSF3
16 brucellosis 29.9 TNF SELL MPO
17 lymphoma, hodgkin, classic 29.9 IL3 CSF3 CSF2
18 allergic hypersensitivity disease 29.8 TNF SELL IL3 CSF2
19 otitis media 29.8 TNF MPO CSF3
20 appendicitis 29.8 TNF MPO CSF3
21 mucositis 29.7 IL3 CSF3 CSF2
22 thrombocytopenia 29.7 TNF SELL ITGAM IL3 CSF3 CSF2
23 adult respiratory distress syndrome 29.7 TNF MPO CSF3
24 fungal infectious disease 29.6 TNF CSF3 CSF2
25 meningitis 29.6 TNF CSF3 CSF2
26 hypereosinophilic syndrome 29.5 MPO IL3 CSF2
27 pancytopenia 29.5 MPO IL3 CSF3 CSF2 CP
28 neutropenia 29.5 TNF MPO ITGAM IL3 CSF3 CSF2
29 mycobacterium tuberculosis 1 29.5 TNF SELL NAT2 ITGAM
30 pyoderma 29.4 TNF ITGB2 CSF3
31 polycythemia vera 29.4 IL3 CSF3 CSF2
32 myeloid leukemia 29.4 MPO ITGAM IL3 CSF3 CSF2
33 common variable immunodeficiency 29.4 TNF SELL MPO ITGAM
34 myeloma, multiple 29.3 TNF ITGAM IL3 CSF3 CSF2
35 exanthem 29.3 TNF MPO CSF3 CSF2
36 chronic granulomatous disease 29.2 TNF MPO CSF3 CSF2
37 diarrhea 29.2 TNF MPO IL3 CSF3
38 pyoderma gangrenosum 29.2 TNF ITGB2 CSF3
39 leukemia, acute lymphoblastic 29.2 SELL MPO ITGAM IL3 CSF3 CSF2
40 vascular disease 29.1 TNF MPO ITGAM CSF3
41 aplastic anemia 29.1 TNF MPO IL3 CSF3 CSF2
42 severe congenital neutropenia 29.0 TNF MPO IL3 CSF3 CSF2
43 leukemia, chronic myeloid 29.0 MPO IL3 CSF3 CSF2
44 myelofibrosis 29.0 TNF MPO ITGAM IL3 CSF3
45 lymphoma, non-hodgkin, familial 29.0 TNF SELL ITGAM IL3 CSF3 CSF2
46 pulmonary disease, chronic obstructive 29.0 TNF MPO ITGAM CSF2
47 lung disease 28.9 TNF MPO CSF3 CSF2
48 leukemia, acute myeloid 28.9 TNF MPO ITGAM IL3 CSF3 CSF2
49 leishmaniasis 28.9 TNF SELL ITGB2 ITGAM
50 gastroenteritis 28.9 TNF IL3 CSF3 CSF2 CP

Graphical network of the top 20 diseases related to Granulocytopenia:



Diseases related to Granulocytopenia

Symptoms & Phenotypes for Granulocytopenia

MGI Mouse Phenotypes related to Granulocytopenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 CP CSF2 CSF3 ITGAM ITGB2 MPO
2 immune system MP:0005387 9.32 CP CSF2 CSF3 ITGAM ITGB2 LAP3

Drugs & Therapeutics for Granulocytopenia

Drugs for Granulocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
2
Cefpirome Approved Phase 4 84957-29-9 5479539
3
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
7
Ibuprofen Approved Phase 4 15687-27-1 3672
8
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
9 Antacids Phase 4
10 Anti-Ulcer Agents Phase 4
11 Proton Pump Inhibitors Phase 4
12 Anti-Bacterial Agents Phase 4
13 Norgestimate, ethinyl estradiol drug combination Phase 4
14 Antibiotics, Antitubercular Phase 4
15 Psychotropic Drugs Phase 4
16 Dopamine agonists Phase 4
17 Dopamine Agents Phase 4
18 Dopamine Antagonists Phase 4
19 Serotonin Receptor Agonists Phase 4
20 Antidepressive Agents Phase 4
21 Serotonin 5-HT1 Receptor Agonists Phase 4
22 Anticonvulsants Phase 4
23 Antirheumatic Agents Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Analgesics Phase 4
26 Cyclooxygenase Inhibitors Phase 4
27 Antipyretics Phase 4
28
dipyrone Phase 4 522325
29 Anti-Inflammatory Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Neurotransmitter Agents Phase 4
32 Sodium Channel Blockers Phase 4
33 Diuretics, Potassium Sparing Phase 4
34 Adrenergic Agents Phase 4
35 Adrenergic Antagonists Phase 4
36 Sympatholytics Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Adrenergic beta-Antagonists Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
40
Deferasirox Approved, Investigational Phase 2, Phase 3 201530-41-8 5493381
41
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
42
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
43
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
44
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
45
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
46
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
47
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
48
Clozapine Approved Phase 3 5786-21-0 2818
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
50
Deferoxamine Approved, Investigational Phase 3 70-51-9 2973

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
2 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
3 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute and Subacute Low Back Pain: A Randomized, Factorial Trial Recruiting NCT04111315 Phase 4 Metamizole Sodium;Ibuprofen 600 mg
6 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
7 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
8 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
9 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
10 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
11 Granulocyte Transfusion Study Completed NCT00000581 Phase 3
12 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
13 Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
14 Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed NCT00350662 Phase 3 Deferiprone (L1);Desferrioxamine
15 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
16 A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
17 Metoclopramide as Treatment of Clozapine-induced Hypersalivation Completed NCT02222220 Phase 3 Metoclopramide;placebo
18 The Effect of Granulocyte-colony Stimulating Factor (G-CSF) on Minimal Residual Disease (MRD) After Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Recruiting NCT03665480 Phase 2, Phase 3 G-SCF
19 Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 Not yet recruiting NCT04360122 Phase 3 Levamisole;Isoprinosine;Levamisole and Isoprinosine
20 Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients Completed NCT02465801 Phase 2 HSA-GCSF 1.2 mg;HSA-GCSF 1.5 mg;GCSF
21 Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients Completed NCT03251768 Phase 2 rHSA-GCSF 2.4mg;GCSF
22 Phase II Randomised Study of the Safety, Efficacy and Pharmacokinetics of Caspofungin (CAS), Liposomal Amphotericin B (LAMB) or the Combination of Caspofungin With Liposomal Amphotericin B for Patients After Stem-Cell Transplantation Completed NCT00148148 Phase 2 caspofungin;liposomal amphotericin B
23 Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients Completed NCT00349453 Phase 2 Deferiprone (L1);Deferiprone (L1);Desferrioxamine
24 B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
25 Trimetazidine as an Adjunct to Enhance Clopidogrel Response: The TRACER Study. Completed NCT03603249 Phase 2 Trimetazidine
26 The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome Completed NCT02477631 Phase 2 Deferiprone
27 An Open,Multicenter Clinic Trial of the Effectiveness,Safety and Pharmacokinetics in the Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Local Caspofungin Recruiting NCT03857399 Phase 2 Caspofungin
28 Clinical Study of Allogeneic Granulocyte Infusion in the Treatment of Patients With Advanced Cancer Recruiting NCT04124666 Phase 1, Phase 2
29 Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL). Active, not recruiting NCT01762202 Phase 2 Cyclophosphamide;Fludarabine;Ofatumumab
30 Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA) Active, not recruiting NCT00907283 Phase 2 Deferiprone
31 A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Terminated NCT00001962 Phase 2 Daclizumab
32 A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy Completed NCT00000673 Phase 1 Ganciclovir
33 A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma Completed NCT00000681 Phase 1 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Zidovudine;Sargramostim
34 Efficacy and Safety Phase Ib Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients Completed NCT03246009 Phase 1 rHSA/GCSF;rHSA/GCSF;rHSA/GCSF;rHSA/GCSF;rHSA/GCSF;rHSA/GCSF
35 A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma Completed NCT00091143 Phase 1 fludarabine phosphate
36 PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT Completed NCT00019032 Phase 1
37 Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia Completed NCT00076180 Phase 1
38 An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet Completed NCT01948024 Phase 1 SAPHRIS;Asenapine
39 Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study Unknown status NCT01946919
40 Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease Approved for marketing NCT00293098 deferiprone
41 Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data Completed NCT00005307
42 Drug Etiology of Aplastic Anemia and Related Dyscrasias Completed NCT00005302
43 A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine Completed NCT00002263 Zidovudine;Sargramostim
44 A Controlled, Randomized Phase II Study of the Safety and Efficacy of Combined Therapy With Ganciclovir and Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone for the Treatment of Sight-Threatening Cytomegalovirus Retinitis in AIDS Patients Completed NCT00000989 Zidovudine;Sargramostim;Ganciclovir
45 Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) Completed NCT01138618
46 Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder Completed NCT00573287 clozapine;risperidone
47 Natural History and Molecular Characterization of Benign Ethnic Neutropenia in Individuals of African Descent Completed NCT00059423
48 Etoricoxib as a Pre-emptive Analgesic in Therapeutic Arthroscopy Completed NCT00738608
49 A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease Completed NCT02685514
50 Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA) Completed NCT01815411

Search NIH Clinical Center for Granulocytopenia

Genetic Tests for Granulocytopenia

Anatomical Context for Granulocytopenia

MalaCards organs/tissues related to Granulocytopenia:

40
Bone, Bone Marrow, Lung, Breast, Neutrophil, Myeloid, Liver

Publications for Granulocytopenia

Articles related to Granulocytopenia:

(show top 50) (show all 6378)
# Title Authors PMID Year
1
Agranulocytosis in dengue hemorrhagic fever: a neglected condition. 61 54
20462096 2010
2
Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine. 61 54
20305597 2010
3
Agranulocytosis following phenytoin-induced hypersensitivity syndrome. 61 54
18774664 2009
4
Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis. 61 54
18613811 2008
5
Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. 54 61
18489081 2008
6
Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. 54 61
18181220 2008
7
The impact of long-term haemofiltration (continuous veno-venous haemofiltration) on cell-mediated immunity during endotoxaemia. 61 54
17567268 2007
8
Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. 61 54
17602675 2007
9
[Docetaxel in the treatment of advanced breast cancer ]. 61 54
17152498 2006
10
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. 61 54
16595571 2006
11
[Idiosyncratic drug-induced agranulocytosis]. 54 61
16043267 2006
12
Granulocyte-Colony Stimulating Factor (G-CSF) Therapy in Antithyroid Drug-induced Agranulocytosis. 61 54
16006735 2005
13
Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? 54 61
15785251 2005
14
Serum concentrations of granulocyte colony-stimulating factor (G-CSF) in antithyroid drug-induced agranulocytosis. 54 61
15644577 2004
15
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. 61 54
15538122 2004
16
Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis. 61 54
14984824 2004
17
NQO2 gene is associated with clozapine-induced agranulocytosis. 54 61
14617031 2003
18
Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. 54 61
12702898 2003
19
[Agranulocytosis and acute coronary syndrome in apathetic hyperthyroidism]. 54 61
14692133 2003
20
Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor. 61 54
12661801 2003
21
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. 54 61
12424538 2002
22
Hematopoietic growth factors in drug-induced agranulocytosis. 54 61
12186123 2002
23
Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. 61 54
11959056 2002
24
Agranulocytosis associated with lamotrigine in a patient with low-grade glioma. 54 61
11903469 2002
25
Sudden termination of G-CSF injection leads to apoptosis of a large proportion of increased granulocytes. 61 54
11496310 2001
26
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. 54 61
11255275 2001
27
G-CSF plasma levels in clozapine-induced neutropenia. 54 61
11094146 2000
28
Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. 54 61
11147929 2000
29
Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. 54 61
11140884 2000
30
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia. 61 54
10937789 2000
31
Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent--a case report. 54 61
10917583 2000
32
[Do hematopoietic growth factors have a role in the treatment of drug-induced agranulocytosis?]. 54 61
10942973 2000
33
The effect of CVVHD and endotoxin on the oxidative burst, adhesion molecules and distribution in tissues of granulocytes. 54 61
10945396 2000
34
Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro. 54 61
10792393 2000
35
[Agranulocytosis in acute hepatitis B in an HIV seropositive patient]. 61 54
10738502 2000
36
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. 61 54
10739170 2000
37
Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. 61 54
11014957 2000
38
Treatment of antithyroid drug-induced agranulocytosis by granulocyte colony-stimulating factor: a case of primum non nocere. 61 54
10560960 1999
39
The use of recombinant human G-CSF in the treatment of propylthiouracil-induced agranulocytosis. 61 54
10695110 1999
40
Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. 61 54
10071282 1999
41
Treatment of drug-induced agranulocytosis with haematopoietic growth factors: a review of the clinical experience. 54 61
18031129 1999
42
Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. 54 61
10221368 1999
43
Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. 61 54
10037073 1999
44
Fever or a soar throat after start of antithyroidal drugs? A medical emergency. 54 61
9803142 1998
45
A multi-center safety trial of the oral iron chelator deferiprone. 61 54
9668543 1998
46
Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease. 61 54
9578815 1998
47
Successful treatment of a patient with Graves' disease on hemodialysis complicated by antithyroid drug-induced granulocytopenia and angina pectoris. 54 61
9292952 1997
48
Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. 61 54
9292945 1997
49
The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. 61 54
9271776 1997
50
Recombinant human granulocyte colony-stimulating factor in treatment of methimazole-induced agranulocytosis. 54 61
15251798 1997

Variations for Granulocytopenia

Expression for Granulocytopenia

Search GEO for disease gene expression data for Granulocytopenia.

Pathways for Granulocytopenia

Pathways related to Granulocytopenia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 TNF ITGB2 ITGAM IL3 CSF3 CSF2
2
Show member pathways
13.19 TNF ITGB2 ITGAM IL3 CSF3 CSF2
3 12.4 TNF MPO ITGB2 IL3
4
Show member pathways
12.35 TNF ITGB2 IL3 CSF2
5 12.09 MPO ITGAM IL3 CSF2
6 11.98 MPO ITGB2 ITGAM
7 11.96 SELL ITGB2 ITGAM
8 11.82 TNF ITGB2 ITGAM
9 11.71 TNF ITGB2 CSF2
10 11.68 TNF ITGB2 ITGAM CSF2
11 11.61 TNF ITGB2 ITGAM
12
Show member pathways
11.6 TNF IL3 CSF2
13 11.55 TNF ITGAM IL3 CSF3 CSF2
14 11.51 TNF CSF3 CSF2
15 11.49 TNF SELL ITGAM CSF2
16 11.46 TNF ITGB2 ITGAM
17 11.37 TNF ITGB2 CSF3
18 11.34 TNF CSF3 CSF2
19 11.31 TNF ITGB2 ITGAM
20 11.29 IL3 CSF3 CSF2
21 11.24 TNF MPO ITGB2 ITGAM
22 11.23 TNF SELL MPO ITGAM IL3 CSF3
23 10.8 TNF MPO
24 10.78 TNF ITGB2 ITGAM IL3 CSF3 CSF2
25 10.72 TNF IL3 CSF3 CSF2

GO Terms for Granulocytopenia

Cellular components related to Granulocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF MPO IL3 HYOU1 CSF3 CSF2
2 extracellular exosome GO:0070062 9.76 NQO2 MPO LAP3 ITGB2 ITGAM HYOU1
3 external side of plasma membrane GO:0009897 9.62 TNF SELL ITGB2 ITGAM
4 extracellular space GO:0005615 9.56 TNF MPO ITGAM IL3 CSF3 CSF2
5 integrin alphaM-beta2 complex GO:0034688 8.62 ITGB2 ITGAM

Biological processes related to Granulocytopenia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.71 TNF SELL ITGB2 ITGAM
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 TNF IL3 CSF2
3 leukocyte tethering or rolling GO:0050901 9.54 TNF SELL
4 positive regulation of superoxide anion generation GO:0032930 9.52 ITGB2 ITGAM
5 toll-like receptor 4 signaling pathway GO:0034142 9.51 ITGB2 ITGAM
6 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.49 TNF ITGB2
7 amyloid-beta clearance GO:0097242 9.48 ITGB2 ITGAM
8 positive regulation of podosome assembly GO:0071803 9.46 TNF CSF2
9 cellular extravasation GO:0045123 9.37 TNF ITGB2
10 negative regulation of dopamine metabolic process GO:0045963 9.32 ITGB2 ITGAM
11 positive regulation of neutrophil degranulation GO:0043315 9.26 ITGB2 ITGAM
12 positive regulation of prostaglandin-E synthase activity GO:2000363 9.16 ITGB2 ITGAM
13 microglial cell activation GO:0001774 9.13 TNF ITGB2 ITGAM
14 cytokine-mediated signaling pathway GO:0019221 9.1 TNF ITGB2 ITGAM IL3 CSF3 CSF2

Molecular functions related to Granulocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 TNF IL3 CSF3 CSF2
2 cargo receptor activity GO:0038024 9.16 ITGB2 ITGAM
3 complement component C3b binding GO:0001851 8.62 ITGB2 ITGAM

Sources for Granulocytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....